82 related articles for article (PubMed ID: 16549901)
1. Long-term treatment of thrombosis with enoxaparin in pediatric and adolescent patients.
Merkel N; Gunther G; Schobess R
Acta Haematol; 2006; 115(3-4):230-6. PubMed ID: 16549901
[TBL] [Abstract][Full Text] [Related]
2. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant.
Michaels LA; Gurian M; Hegyi T; Drachtman RA
Pediatrics; 2004 Sep; 114(3):703-7. PubMed ID: 15342842
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy data on childhood venous thrombosis treated with a low molecular weight heparin: an open-label pilot study of once-daily versus twice-daily enoxaparin administration.
Schobess R; Düring C; Bidlingmaier C; Heinecke A; Merkel N; Nowak-Göttl U
Haematologica; 2006 Dec; 91(12):1701-4. PubMed ID: 17145610
[TBL] [Abstract][Full Text] [Related]
4. [Outpatient treatment of deep vein thrombosis with low-molecular-weight heparins. Experience from an open, prospective study in daily practice].
Heidenreich C; Hohmann V; Bramlage P
Med Klin (Munich); 2009 Jan; 104(1):20-7. PubMed ID: 19142593
[TBL] [Abstract][Full Text] [Related]
5. Enoxaparin use in the neonatal intensive care unit: experience over 8 years.
Malowany JI; Knoppert DC; Chan AK; Pepelassis D; Lee DS
Pharmacotherapy; 2007 Sep; 27(9):1263-71. PubMed ID: 17723080
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of enoxaparin dosing requirements in infants and children. Better dosing to achieve therapeutic levels.
Bauman ME; Belletrutti MJ; Bajzar L; Black KL; Kuhle S; Bauman ML; Patricia Massicotte M
Thromb Haemost; 2009 Jan; 101(1):86-92. PubMed ID: 19132193
[TBL] [Abstract][Full Text] [Related]
7. Treatment of deep venous thrombosis with low molecular weight heparin in pediatric cancer patients: safety and efficacy.
Tousovska K; Zapletal O; Skotakova J; Bukac J; Sterba J
Blood Coagul Fibrinolysis; 2009 Oct; 20(7):583-9. PubMed ID: 19620843
[TBL] [Abstract][Full Text] [Related]
8. Fluctuations of anti-Xa concentrations during maintenance enoxaparin therapy for neonatal thrombosis.
Lulic-Botica M; Rajpurkar M; Sabo C; Tutag-Lehr V; Natarajan G
Acta Paediatr; 2012 Apr; 101(4):e147-50. PubMed ID: 22211705
[TBL] [Abstract][Full Text] [Related]
9. Thromboelastogram-guided enoxaparin dosing does not confer protection from deep venous thrombosis: a randomized controlled pilot trial.
Louis SG; Van PY; Riha GM; Barton JS; Kunio NR; Underwood SJ; Differding JA; Rick E; Ginzburg E; Schreiber MA
J Trauma Acute Care Surg; 2014 Apr; 76(4):937-42; discussion 942-3. PubMed ID: 24662855
[TBL] [Abstract][Full Text] [Related]
10. The impact of quality and duration of enoxaparin therapy on recurrent venous thrombosis in children.
Estepp JH; Smeltzer M; Reiss UM
Pediatr Blood Cancer; 2012 Jul; 59(1):105-9. PubMed ID: 22106013
[TBL] [Abstract][Full Text] [Related]
11. Dosing and monitoring of enoxaparin (Low molecular weight heparin) therapy in children.
Ignjatovic V; Najid S; Newall F; Summerhayes R; Monagle P
Br J Haematol; 2010 Jun; 149(5):734-8. PubMed ID: 20346012
[TBL] [Abstract][Full Text] [Related]
12. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
13. Dosing and monitoring of enoxaparin therapy in children: experience in a tertiary care hospital.
Andrade-Campos MM; Montes-Limón AE; Fernandez-Mosteirin N; Salvador-Osuna C; Torres M; Lucia-Cuesta JF; Rubio-Felix D
Blood Coagul Fibrinolysis; 2013 Mar; 24(2):194-8. PubMed ID: 23358201
[TBL] [Abstract][Full Text] [Related]
14. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
[TBL] [Abstract][Full Text] [Related]
15. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Sarasin FP; Bounameaux H
Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
[TBL] [Abstract][Full Text] [Related]
16. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial.
Veiga F; Escribá A; Maluenda MP; López Rubio M; Margalet I; Lezana A; Gallego J; Ribera JM
Thromb Haemost; 2000 Oct; 84(4):559-64. PubMed ID: 11057850
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study.
Massicotte P; Adams M; Marzinotto V; Brooker LA; Andrew M
J Pediatr; 1996 Mar; 128(3):313-8. PubMed ID: 8774496
[TBL] [Abstract][Full Text] [Related]
18. Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing.
Bauman ME; Black KL; Bauman ML; Belletrutti M; Bajzar L; Massicotte MP
Thromb Res; 2009 Apr; 123(6):845-7. PubMed ID: 19038418
[TBL] [Abstract][Full Text] [Related]
19. Treatment of deep vein thrombosis with continuous intravenous infusion of LMWH in children--an alternative to subcutaneous application when needed.
Blatný J; Fiamoli V
Vnitr Lek; 2009 Mar; 55(3):227-32. PubMed ID: 19378852
[TBL] [Abstract][Full Text] [Related]
20. Deep venous thrombosis in children and adolescents.
Levy ML; Granville RC; Hart D; Meltzer H
J Neurosurg; 2004 Aug; 101(1 Suppl):32-7. PubMed ID: 16206969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
